Telephone
61.2.4044.4585
Address
Level 5 360 Kent Street Sydney, New South Wales (NSW) 2000
Description
Elixinol Wellness Ltd. engages in the sale of nutraceutical and related hemp products. It manufactures and distributes industrial hemp products and early stage medical cannabis business focusing on the importation, cultivation, manufacture and distribution of CBD and THC products. The company was founded by Paul Benhaim on September 4, 2017 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.03
Trade Value (12mth)
AU$2,352.00
1 week
-13.33%
1 month
85.71%
YTD
-35%
1 year
-55.17%
All time high
5.11818
EPS 3 yr Growth
-93.700%
EBITDA Margin
-131.60%
Operating Cashflow
-$8m
Free Cash Flow Return
-53.40%
ROIC
-69.30%
Interest Coverage
-130.70
Quick Ratio
2.20
Shares on Issue (Fully Dilluted)
360m
HALO Sector
Healthcare
Next Company Report Date
27-Feb-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 18 |
EXL Sydney Wholesale Investor Presentation
×
EXL Sydney Wholesale Investor Presentation |
31 May 23 |
2023 AGM - CEO's Presentation
×
2023 AGM - CEO's Presentation |
31 May 23 |
2023 AGM - Chair's Address
×
2023 AGM - Chair's Address |
31 May 23 |
2023 AGM - Voting Results
×
2023 AGM - Voting Results |
31 May 23 |
Amended Constitution
×
Amended Constitution |
31 May 23 |
Notification regarding unquoted securities - EXL
×
Notification regarding unquoted securities - EXL |
31 May 23 |
Notification regarding unquoted securities - EXL
×
Notification regarding unquoted securities - EXL |
31 May 23 |
Appendix 3Y - Helen Wiseman
×
Appendix 3Y - Helen Wiseman |
31 May 23 |
Appendix 3Y - David Fenlon
×
Appendix 3Y - David Fenlon |
31 May 23 |
Appendix 3Y - Ronald Dufficy
×
Appendix 3Y - Ronald Dufficy |
31 May 23 |
Application for quotation of securities - EXL
×
Application for quotation of securities - EXL |
31 July 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 January 23 |
Quarterly Update and Appendix 4C
×
Quarterly Update and Appendix 4C |
31 January 22 |
Quarterly Update and Appendix 4C
×
Quarterly Update and Appendix 4C |
31 August 23 |
Application for quotation of securities - EXL
×
Application for quotation of securities - EXL |
31 August 23 |
Notification regarding unquoted securities - EXL
×
Notification regarding unquoted securities - EXL |
31 August 20 |
H1 FY2020 Results Presentation
×
H1 FY2020 Results Presentation |
30 October 23 |
Quarterly Update & Appendix 4C
×
Quarterly Update & Appendix 4C |
30 November 22 |
Proposed issue of securities - EXL
×
Proposed issue of securities - EXL |
30 November 22 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
30 March 20 |
Annual Report
×
Annual Report |
30 June 20 |
Notice of Annual General Meeting & Proxy Form
×
Notice of Annual General Meeting & Proxy Form |
30 July 20 |
2020 AGM - CEO Presentation
×
2020 AGM - CEO Presentation |
30 December 21 |
Appendix 3Y - Paul Benhaim
×
Appendix 3Y - Paul Benhaim |
30 December 21 |
Change in Substantial Holding - Paul Benhaim
×
Change in Substantial Holding - Paul Benhaim |
30 August 23 |
H1 FY2023 Appendix 4D and Interim Report
×
H1 FY2023 Appendix 4D and Interim Report |
30 August 23 |
H1 FY2023 Results Announcement
×
H1 FY2023 Results Announcement |
30 August 23 |
H1 FY2023 Results Presentation
×
H1 FY2023 Results Presentation |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.